Glepaglutide
- Generic Name
- Glepaglutide
- Drug Type
- Biotech
- CAS Number
- 914009-86-2
- Unique Ingredient Identifier
- 4M3C1913N6
- Background
Glepaglutide is under investigation in clinical trial NCT00868660 (Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose).
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04991311
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 129
- Registration Number
- NCT04881825
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇪Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Universitätsklinikum Frankfurt, Frankfurt, Germany
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 85
- Registration Number
- NCT04318743
- Locations
- 🇳🇱
PRA Health Sciences- Location Martini, Groningen, NZ, Netherlands
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT04178447
- Locations
- 🇵🇱
Specjalistyczne Centrum Medyczne - Prywatny Szpital, Kraków, Poland
🇭🇺Fázis I-es Klinikai Farmakológiai, Budapest, Hungary
🇭🇺Szent Imre Egyetemi Oktatókórház, Budapest, Hungary
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 145
- Registration Number
- NCT03905707
- Locations
- 🇬🇧
St Mark's Hospital, Harrow, United Kingdom
🇺🇸Mayo Clinic College of Medicine, Rochester, Minnesota, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 106
- Registration Number
- NCT03690206
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇫🇷Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 75
- Registration Number
- NCT03279302
- Locations
- 🇺🇸
Covance CRU, Dallas, Texas, United States
A Phase 2 Trial Testing ZP1848 in Patients With SBS
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT02690025
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 66
- Registration Number
- NCT00868660
- Locations
- 🇺🇸
CRI Worldwide, Willingboro, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.